Skip to content

Posts tagged ‘oncology new products consultant’

Insights from AACR Molecular Targets Meeting

November 22nd, 2011


San Francisco Transamerica Pyramid © Pieter Droppert 225x300 Insights from AACR Molecular Targets MeetingThere was a lot of interesting science at the recent AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics international conference in San Francisco.

In particular, the poster sessions offered the opportunity to discuss pre-clinical and early drug development work, and share insights into pathways and mechanisms of action. If you are in new product development, it’s a key meeting to attend.

What was the news at AACR molecular targets?

Sally Church on Pharma Strategy Blog aggregated the live tweets from the joint AACR-NCI-EORTC meeting, although the absence of wifi in the plenary sessions meant that there were fewer tweets than might have been expected.

Sally has written about some of the data presented on breast cancer at the meeting. In her insightful post she reviews the Syndax data for entinostat in second-line ER/PR+ breast cancer, and also asks whether ALK is a new target in inflammatory breast cancer (IBC)?

From what was heard at the meeting, there will be a lot of new breast cancer data at the forthcoming San Antonio Breast Cancer Symposium (SABCS) that Sally will also be attending.

More insights from AACR molecular targets will be available on Pharma Strategy Blog in the next few days.

Meanwhile on Biotech Strategy Blog, Pieter Droppert has written about some of the sessions he attended in San Francisco on:

Next year’s 2012 molecular targets meeting will be in Dublin, good news for all those who like Guinness!

Understanding the market for PARP inhibitors

May 13th, 2011


One of our areas of focus at Icarus Consultants is helping pharma, biotech clients with their commercial strategy to bring new products to market. Sally Church worked in oncology new products at Novartis and brought Gleevec to market in the United States, so has first hand experience of what it takes to make this happen.

Key to new product success is understanding the market opportunity, and focusing your drug on targets that have both commercial and clinical justification.  We spend a lot of our time writing powerpoint presentations that help clients make strategic new product development marketing and commercial decisions.

On Pharma Strategy Blog, Sally Church takes a look at the market for PARP inhibitors such as iniparib, olaparib and veliparib.  She’s been writing about them since 2006!

Sally discusses the clinical trials that have taken place, and how poor trial design has contributed to the lack of success.   You can read Sally’s in-depth review of what’s happening with the clinical development of PARP inhibitors on Pharma Strategy Blog.

Understanding the mechanism of rituximab resistance in Non-Hodgkins Lymphoma (NHL)

April 28th, 2011


Rituximab (Rituxan®) is a monoclonal antibody used to treat Non-Hodgkins Lymphoma (NHL).  It targets the CD20 marker on B-cells from which most NHL develops.

Sally Church on Pharma Strategy Blog asks why do some patients develop resistance to rituximab, while others do not?

The answer according to recent research reviewed by Sally is that some patients develop C-terminal deletion mutations of CD20 that are part of the mechanism that causes resistance to rituximab in Non-Hodgkins Lymphoma (NHL).

As Sally points out in her blog post, understanding rituximab resistance in lymphoma can help identify patients who need to change treatments earlier.  It may also lead to new product development opportunities e.g. targeting a different molecule such as CD22.

Zebrafish as a platform for cancer gene discovery

March 31st, 2011


Nature Cover March 24 2011 Zebrafish as a platform for cancer gene discoveryIcarus Consultants’ oncology new products guru, Sally Church, has published a fascinating post on Pharma Strategy Blog on how Zebrafish models of melanoma are providing new drug targets.

Sally discusses recent research published in Nature that shows the histone methyltransferase SETDB1 is an oncogene that accelerates melanoma formation in co-operation with BRAF(V600E).

What makes this research exciting is the potential of zebrafish as a platform for cancer gene discovery.

AACR 2011 annual meeting in Orlando

March 29th, 2011


Orange County Convention Center Orlando 300x225 AACR 2011 annual meeting in OrlandoSally Church, PhD will be attending the American Association for Cancer Research (AACR) 2011 annual meeting in Orlando that starts this Saturday.

This meeting offers insight into the next generation of PI3K, Akt and mTOR inhibitors, and which compounds have promise for future clinical development.

This is Sally’s favorite meeting of the year as it gives a relaxed opportunity to meet with leading scientists in preclinical drug development and translational medicine.

There will be over 5000 posters, so we hope Sally goes with comfortable shoes for all the walking!  You can read updates from the meeting on Pharma Strategy Blog.

AACR PI3-Kinase Conference Coverage #PI3K

February 24th, 2011


Sally Church on Pharma Strategy Blog will be providing live coverage of the AACR PI3-Kinase conference that starts today in San Francisco.

Sally AKA @MaverickNY will be live tweeting from the event that starts at 7pm (california time) today, Thursday, February 24 and runs through Sunday morning, February 27. The Cover it Live widget on her blog will be aggregating all the tweets that use the conference hashtag #PI3K, so if you are unable to be in San Francisco, you can follow what’s happening by clicking here.

This AACR special conference has an impressive line-up of leading key opinion leaders and experts in the field.  The keynote session this evening is on “Targeting PI3K/mTOR in breast cancer” by Jose Baselga, from Mass General.  The session chair is Lewis Cantley.

Some of the new products in development that will be discussed at the meeting include: GSK2126458, INK1117, AZD8055, MK-2206 and SAR245408 (XL147).  If you are interested in purchasing an Icarus Consultants in-depth meeting report, do contact us.

AACR Conference on Targeting PI3K/mTOR Signaling in Cancer

February 22nd, 2011


Sally Church, PhD will be attending the American Association for Cancer Research (AACR) conference on the PI3K/mTOR pathway being held in San Francisco later this week, February 24-27.

Meetings such as this offer insight into the next generation of PI3K, Akt and mTOR inhibitors, and which compounds have promise for future clinical development.

If you are going to be in San Francisco for the meeting and would like to find out more about our capabilities and how we help commercial teams with new product development strategy, please contact us. It is always a pleasure to make new contacts.